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A21Abstracts
suggest a multi-pronged approach including focus groups and
surveys of physicians, implementation of clinical guidelines, and
ongoing feedback in an Israeli MCO.
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INFECTIONS
He J,Wang C, Grifﬁn B, Smith J, Mahoney A, Burleigh E
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OBJECTIVES: Serious candida infections have been treated with
a variety of patterns of antifungal drugs. This study focused on
the outcomes of hospitalized patients treated with antifungal
drugs and examined drug switching approaches in actual prac-
tice. METHODS: A retrospective study was conducted among a
population of 9746 serious candida infection patients treated
with antifungal drugs during the time period of February 2003
to June 2005. Data was collected from 441 hospitals out of the
Solucient® ACTrackertm database. Patients were categorized
into an adherence group with patients staying in aggressive drugs
(IV forms of amphotericin B, amphotericin B lipids, cancidas and
vfend) and a switching group with patients who switched from
aggressive drugs to non-aggressive and less expensive drugs (oral
forms only of amphotericin B, sporanox, diﬂucan & vfend).
Mortality and length of stay (LOS) of the two groups were com-
pared by Chi square and T test. Further analysis was followed
by using Logistics regression and ANCOVA analysis with con-
trolled inﬂuencing factors such as co-morbidities. RESULTS: The
drug switching patients group was found to have signiﬁcantly
higher mortality rate (0.246 vs 0.160, Chi = 29.68, p < 0.001)
and longer LOS (36.45 vs 27.73, t = 7.67, p < 0.001) as com-
pared to adherence group. The higher mortality in switching
group was supported by Logistic regression results with the 
following confounding factors controlled: age (OR 1.013,
CI:1.009–1.017), septicemia (OR 1.231, CI:1.055–1.451),
kidney disease(OR 1.288, CI:1.091–1.52), ER(OR 1.362,
CI:1.083–1.712) and other candida (OR 1.440,
CI:1.039–1.996). The extended LOS also was found by using
ANCOVA with confounding factors adjusted including mycoses,
ER admission, Medicare payment. CONCLUSIONS: The study
demonstrated that switching aggressively treated patients to
cheaper and less aggressive drugs caused higher mortality and
extended hospital stay. More extensive clinical and economic
outcome studies are needed to understand antifungal drug treat-
ment in candida infection patients.
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TRENDS IN HIV TREATMENT EXPERIENCE AND OUTCOMES
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OBJECTIVES: Describe US treatment experience trends, shifts
in employment status, insurance, and CD4 counts of HIV/AIDS
patients since the introduction of highly active antiretroviral
therapy (HAART) in 1996. METHODS: HIV-infected patients
(n = 3203) treated at US clinics from 1996–2004 as part of the
HIV Insight database* were studied. Longitudinal patient
records were analyzed to track the changing distribution of anti-
retroviral treatment experience by year. Patients having at least
six months of follow-up and enrollment in the reporting year
were classiﬁed into four treatment experience groups: Nucleo-
side Reverse Transcriptase Inhibitors (NRTI), Non-Nucleoside
Reverse Transcriptase Inhibitors (NNRTI), Protease Inhibitor
(PI), and 3-class experience. Demographic shifts were observed
for: employment and disability status, and primary insurance
type. CD4 counts were examined by treatment experience level.
RESULTS: Of the 3203 patients with active enrollment, 2552
were treated. Average follow-up was 3.84 and 4.33 years, respec-
tively. The percentage of patients with treatment experience
increased substantially in all 4 groups (1996–2004): NRTI (48%,
98%), NNRTI (4%, 67%), PI (25%, 63%), 3-class (<1%, 36%).
The percentage of patients working (part/full-time) increased
from 49% to 62% from 1996 to 2004. The percentage of dis-
abled patients decreased from 22% to 15%. Primary insurance
coverage for treated patients was distributed as follows
(1996–2004): Private insurance (50%, 60%), Medicare (10%,
7.4%), Medicaid (30%, 20%), AIDS Drug Assistance Programs
(ADAP) (2.7%, 5.0%), and Other (7.5%, 8.4%). Lower CD4
counts correspond with more treatment experienced patients.
CONCLUSIONS: While increased use of HAART therapy cor-
responds with better employment status and increased private
insurance, patients who have more treatment experience have
lower CD4 counts, signaling a need for more effective treatment
options. *Includes data from the CDC’s HIV Outpatient Study,
and other US HIV care-sites funded by Cerner Corporation. The
ﬁndings and conclusions are the authors’ and don’t represent the
views of the CDC/US DHHS.
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OBJECTIVES: There is a paucity of published research address-
ing how the Infectious Disease Society of America guidelines for
empiric treatment of CAP are implemented in clinical practice.
The current study was designed to describe antibiotic treatment
patterns among Medicare managed care patients with CAP
treated in ambulatory settings in light of these guidelines.
METHODS: This study used claims data from a Medicare
managed care organization located throughout geographically
diverse regions of the US. Patients with pneumonia treated with
any antibiotic in ambulatory settings during 2004 were retro-
spectively identiﬁed via ICD-9CM codes (481–486). Recent
antibiotic use was identiﬁed through NDC and J codes, and
deﬁned as receipt of any antibiotics within 90 days prior to the
date of diagnosis. Individuals were divided into four groups as
per guidelines: G1) previously healthy without recent antibiotics;
G2) previously healthy with recent antibiotics; G3) with comor-
bidities (including COPD, diabetes, renal or congestive heart
failure, or malignancy) and without recent antibiotics; AND G4)
with comorbidities and recent antibiotics. RESULTS: Of 2186
patients identiﬁed, 59% had comorbidities. The mean age was
76.6 years and 61% were female. Among G1 patients (n = 661),
guideline compliance was 41% (recommended treatment: a
macrolide or doxycycline). For G2 patients (n = 230), guideline
compliance was 40% (recommended treatment: a respiratory
quinolone alone, or an advanced macrolide plus amoxicillin or
augmentin). A high compliance rate was observed among G3
patients with comorbidities and without recent antibiotics (n =
861) (72%; recommended treatment: an advanced macrolide or
respiratory quinolone). For G4 patients with comorbidities and
recent antibiotics (n = 434), guideline compliance was 39% (rec-
ommended treatment: a respiratory quinolone alone or advanced
macrolide plus beta-lactam). CONCLUSION: These data,
reﬂecting a period shortly after the CAP guidelines were pub-
